Articles Related to quiescence
Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery
Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is the only FDA-approved drug labeled for prevention of preterm delivery. This drug is also available as a compounded product from licensed compounding pharmacies. This article reviews the FDA approval history and pharmacy compounding quality control data of 17-OHPC, as well as briefly discusses possible future pharmaceutical development strategies for 17-OHPC.
Editorial Board Members Related to quiescence
Markus Müschen
Professor
Department of Laboratory Medicine
University of California, San Francisco
United States
Department of Laboratory Medicine
University of California, San Francisco
United States
Daniel Lacorazza
Associate Professor
Departments of Pathology and Immunology
Baylor College of Medicine
United States
Departments of Pathology and Immunology
Baylor College of Medicine
United States
Jonathan R. Keller
Principal Investigator
Hematopoiesis and Stem Cell Biology Section
Center for Cancer Research
National Cancer Institute
United States
Hematopoiesis and Stem Cell Biology Section
Center for Cancer Research
National Cancer Institute
United States